Hiroki Takashima

Dr. Hiroki Takashima

Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Journal of Controlled Release
Verified
Journal Article
Open access
RTRyo Tsumura
Ryo Tsumura
SMShino Manabe
Shino Manabe
HTHiroki Takashima
Hiroki Takashima
Yoshikatsu KogaYoshikatsu Koga
Yoshikatsu Koga
MYMasahiro Yasunaga
Masahiro Yasunaga
YMYasuhiro Matsumura
Yasuhiro Matsumura
Antibody-drug conjugates (ADCs) are currently considered to be promising agents for cancer therapy. However, especially in solid tumors, the uneven distribution of ADCs would decrease their efficacy in clinical studies. We suggest that in addition to optimizing ADC components, such as the linker structure and anticancer agent, it is necessary to consider the distribution of the ADC within tumor tissue. In this study, we established three kinds of anti-tissue factor (TF) ADCs: 1849ADC with a low kd, 444ADC with an intermediate kd, and 1084ADC with a high kd. All three of the anti-TF ADCs exhibited almost the same in vitro cytotoxicity and pharmacological and biochemical characteristics, although the binding kinetics parameters differed. In vivo, all ADCs exerted equivalent antitumor effects against small BxPC3 tumors. However, on larger BxPC3 tumors, 1084ADC (higher kd) exerted higher antitumor activity than 1849ADC (lower kd). Furthermore, immunofluorescence staining indicated that 1084ADC was distributed throughout the whole tumor, whereas 1849ADC was mainly localized close to tumor vessels. We conclude that the ADC with a higher kd increased the antitumor effect of because it penetrated and distributed evenly throughout the entire solid tumor. These findings highlight the importance of the kd of a mAb in ADC design.

6 July 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
TATakahiro Anzai
Takahiro Anzai
SSShinji Saijou
Shinji Saijou
HTHiroki Takashima
Hiroki Takashima
MHMisato Hara
Misato Hara
SHShingo Hanaoka
Shingo Hanaoka
MYMasahiro Yasunaga
Masahiro Yasunaga
Development of antibodies against the native structure of membrane proteins with multiple transmembrane domains is challenging because it is difficult to prepare antigens with native structures. Previously, we successfully developed a monoclonal antibody against multi-pass membrane protein TMEM180 by exosome immunization in rats. This approach yielded antibodies that recognized cancer-specific antigens on the exosome. In this study, we performed immunoprecipitation using magnetic beads to identify the antigen of one of the rat antibody clones, 0614, as CD73. We then converted antibody 0614 to human chimeric antibody 0614-5. Glioblastoma (GB) was the cancer type with the highest expression of CD73 in the tumor relative to healthy tissue. An antibody–drug conjugate (ADC) of 0614-5 exerted an antitumor effect on GB cell lines according to expression of CD73. The 0614-5-ADC has potential to be used to treat cancers with high CD73 expression. In addition, our strategy could be used to determine the antigen of any antibody produced by exosome immunization, which may allow the antibody to advance to new antibody therapies.

5 December 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Yoshikatsu KogaYoshikatsu Koga
Yoshikatsu Koga
HTHiroki Takashima
Hiroki Takashima
SKShigehiro Koganemaru
Shigehiro Koganemaru
This Special Issue focuses on the use of therapeutic antibodies in vitro, in vivo, and in clinical studies